234 related articles for article (PubMed ID: 34278008)
21. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy.
Henkenberens C; Oehus AK; Derlin T; Bengel F; Ross TL; Kuczyk MA; Janssen S; Christiansen H; von Klot CAJ
Strahlenther Onkol; 2020 Nov; 196(11):1006-1017. PubMed ID: 32399639
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET.
Gravis G; Autret A; Guibert-Broudic M; Dubergé T; Zemmour C; Carrier P; Salem N; Badinand D; Cartier L; Gross E; Walz J; Pignot G; Brenot-Rossi I
Clin Genitourin Cancer; 2021 Aug; 19(4):346-353. PubMed ID: 33849812
[TBL] [Abstract][Full Text] [Related]
24.
Marzec J; Becker J; Paulsen F; Wegener D; Olthof SC; Pfannenberg C; Schwenck J; Bedke J; Stenzl A; Nikolaou K; la Fougère C; Zips D; Müller AC
Acta Oncol; 2020 Feb; 59(2):149-156. PubMed ID: 31559880
[No Abstract] [Full Text] [Related]
25. Stereotactic Body Radiotherapy for Lymph-Nodal Oligometastatic Prostate Cancer: A Multicenter Retrospective Experience.
Cuccia F; Tamburo M; Piras A; Mortellaro G; Iudica A; Daidone A; Federico M; Zagardo V; Ferini G; Marletta F; Spatola C; Fazio I; Filosto S; Pergolizzi S; Ferrera G
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629732
[No Abstract] [Full Text] [Related]
26. PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study.
Mazzola R; Cuccia F; Pastorello E; Salgarello M; Francolini G; Livi L; Triggiani L; Magrini SM; Ingrosso G; Aristei C; Franzese C; Scorsetti M; Alongi F
Clin Exp Metastasis; 2022 Jun; 39(3):443-448. PubMed ID: 35266063
[TBL] [Abstract][Full Text] [Related]
27. Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease.
Bobrowski A; Metser U; Finelli A; Fleshner N; Berlin A; Perlis N; Kulkarni GS; Chung P; Kuhathaas K; Atenafu EG; Hamilton RJ
Can Urol Assoc J; 2021 Oct; 15(10):E545-E552. PubMed ID: 34665714
[TBL] [Abstract][Full Text] [Related]
28. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer.
Mohan R; Kneebone A; Eade T; Hsiao E; Emmett L; Brown C; Hunter J; Hruby G
Radiat Oncol; 2023 Aug; 18(1):127. PubMed ID: 37528487
[TBL] [Abstract][Full Text] [Related]
30. Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial.
Janssen J; Staal FHE; Brouwer CL; Langendijk JA; de Jong IJ; van Moorselaar RJA; Schuit E; Verzijlbergen JF; Smeenk RJ; Aluwini S
BMC Cancer; 2022 May; 22(1):482. PubMed ID: 35501744
[TBL] [Abstract][Full Text] [Related]
31.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer.
Stefan A Koerber ; Katharina Sprute ; Clemens Kratochwil ; Erik Winter ; Matthias F Haefner ; Sonja Katayama ; Ingmar Schlampp ; Klaus Herfarth ; Klaus Kopka ; Ali Afshar-Oromieh ; Stefanie Zschaebitz ; Tim Holland-Letz ; Peter L Choyke ; Dirk Jaeger ; Markus Hohenfellner ; Uwe Haberkorn ; Juergen Debus ; Frederik L Giesel
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):143-151. PubMed ID: 32405735
[TBL] [Abstract][Full Text] [Related]
33. Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT.
Gomez-Iturriaga A; Casquero Ocio F; Ost P; Fernandez I; Rodeño E; Llarena R; Garcia-Olaverri J; Ortiz de Zarate R; Cacicedo J; Ahtamon A; Bilbao P
Eur J Cancer Care (Engl); 2019 Sep; 28(5):e13093. PubMed ID: 31115124
[TBL] [Abstract][Full Text] [Related]
34. Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer.
Mercier C; Claessens M; De Troyer B; Debacker T; Fransis K; Vandeursen H; Ost P; Dirix P
Front Oncol; 2022; 12():863609. PubMed ID: 35494057
[TBL] [Abstract][Full Text] [Related]
35.
Akdemir EN; Tuncel M; Akyol F; Bilen CY; Baydar DE; Karabulut E; Ozen H; Caglar M
World J Urol; 2019 May; 37(5):813-821. PubMed ID: 30151600
[TBL] [Abstract][Full Text] [Related]
36. Intention-to-Treat Analysis of
Schwenck J; Olthof SC; Pfannenberg C; Reischl G; Wegener D; Marzec J; Bedke J; Stenzl A; Nikolaou K; la Fougère C; Zips D; Müller AC
J Nucl Med; 2019 Oct; 60(10):1359-1365. PubMed ID: 30850491
[TBL] [Abstract][Full Text] [Related]
37. Detection Rate of
Brumberg J; Beckl M; Dierks A; Schirbel A; Krebs M; Buck A; Kübler H; Lapa C; Seitz AK
Biomedicines; 2020 Nov; 8(11):. PubMed ID: 33217931
[TBL] [Abstract][Full Text] [Related]
38.
Fassbind S; Ferraro DA; Stelmes JJ; Fankhauser CD; Guckenberger M; Kaufmann PA; Eberli D; Burger IA; Kranzbühler B
Ann Nucl Med; 2021 Oct; 35(10):1109-1116. PubMed ID: 34185262
[TBL] [Abstract][Full Text] [Related]
39. (68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer : Early efficacy after primary therapy.
Henkenberens C; von Klot CA; Ross TL; Bengel FM; Wester HJ; Merseburger AS; Vogel-Claussen J; Christiansen H; Derlin T
Strahlenther Onkol; 2016 Jul; 192(7):431-9. PubMed ID: 27272755
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Treatment Outcomes of Prostate Cancer Patients With Lymph Node Metastasis Treated With Definitive Radiotherapy: Comparative Analysis of PSMA PET/CT and Conventional Imaging.
Onal C; Guler OC; Erpolat P; Hurmuz P; Sutera P; Deek MP; Elmali A; Yilmaz MT; Koken UH; Yavuz M; Ozyigit G; Tran PT
Clin Nucl Med; 2024 Jun; ():. PubMed ID: 38847441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
